Editas medicine stock price.
With all that said, here are the most exciting genomic stocks that you won’t want to miss out on. NTLA Intellia Therapeutics $37.75 BEAM Beam Therapeutics $30.71 EDIT Editas Medicine $8.16.
Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 17.03% so far this month. During the month of May, Editas Medicine Inc’s stock price has reached a high of $10.71 and a low of $7.69. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas Medicine ...Another Jennifer Doudna co-founded company is Editas Medicine (NASDAQ: EDIT). Like Intellia, Editas is among the gene editing stocks using CRISPR/Cas9 systems to to solve incurable diseases.Find out the current price target and stock forecast for Editas Medicine ... Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85 ...The average Editas Medicine stock forecast 2024 represents a 3.79% increase from the last price of $10.5299997329712. For Editas Medicine stock forecast for 2025, 12 predictions are offered for each month of 2025 with average Editas Medicine stock forecast of $10.98, a high forecast of $12.02, and a low forecast of $10.15.
Apr 3, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ... Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 19.25% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.27. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.48. Year to date, Editas ...
Apr 3, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...
Snap's stock is now far below its all-time high of close to $80 in 2021, but patient investors could see shares reach and exceed that price. Prosper Junior Bakiny has no position in any of the ...Get the LIVE share price of Editas Medicine Inc(EDIT) and stock performance in one place to strengthen your trading strategy in US stocks. Now Start Investing in Editas Medicine Inc on Groww. Editas Medicine Inc. Healthcare. $10.77 +0.24(2.28%) 1D. 1D. 1W. 1M. 1Y. 3Y. 5Y. Performance. Open Price: Prev. Close: Volume: Avg. Volume: …Editas Medicine is a CRISPR company based out of Cambridge, Massachusetts, working "to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines " At the ...Nov 3, 2023 · Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. ... The sustainability of the stock's immediate price movement ... Editas got a bump on Sept. 29 when Stifel analyst Dae Gon Ha increased his 12-month price target for Editas from $9 to $17 and upgraded his position on the biotech stock from hold to buy, saying ...
Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85. The forecasts range from a low of $7.00 to a high of $30.00. The average ...
Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53 . Today 200 Day Moving Average is the resistance level ( 8.45 $).
It's been a tough year for Editas Medicine (EDIT-0.26%) so far. As of the market close on Monday, the stock was down 42%. But shares of Editas were rebounding by 8.2% as of 11:25 a.m. EST on ...Nov 21, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 51.5% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ... Over the past year, shares of gene-editing companies Editas Medicine ( EDIT -0.23%) and CRISPR Therapeutics ( CRSP 6.42%) have shot up 129% and 212%, respectively. Their mouth-watering returns ...The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119 ...11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.Editas Medicine (NASDAQ: EDIT) $10.49 (3.7%) $0.37 Price as of November 22, 2023, 4:00 p.m. ET Key Data Points Current Price $10.49 Daily Change (3.7%) $0.37 Day's …
Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Dec 1, 2023 · Summary of all time highs, changes and price drops for Editas Medicine; Historical stock prices; Current Share Price: US$10.77: 52 Week High: US$11.93: 52 Week Low ... Editas Medicine releases earnings for the most recent quarter on November 3. Analysts predict Editas Medicine will release losses per share of $0.575. Go here to track Editas Medicine stock price ...Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85. The forecasts range from a low of $7.00 to a high of $30.00. The average ...What is the target price for Editas Medicine (EDIT) stock? A. The latest price target for . Editas Medicine (NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023.Dec 1, 2023 · According to the issued ratings of 12 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $13.92 with a high price target of $30.00 and a low price target of $7.00. Learn ... Nov 24, 2023 · Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...It's been a tough year for Editas Medicine (EDIT-0.26%) so far. As of the market close on Monday, the stock was down 42%. But shares of Editas were rebounding by 8.2% as of 11:25 a.m. EST on ...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 9.29% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $8.10. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.71. Year to date, Editas ...Nov 3, 2023 · Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. ... The sustainability of the stock's immediate price movement ... Editas Medicine, Inc. (EDIT) is a clinical-stage genome editing company that develops treatments for cancer and other diseases. The stock price, news, quote and history of EDIT are shown on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield, fair value and more. This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...
Market Cap. $422M. Today's Change. (0.52%) $0.02. Current Price. $3.86. Price as of November 29, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley ...
Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis.
Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ...According to About.com, how long medicine takes to absorb into the stomach depends on the type of medication, whether it is taken with food or on an empty stomach, and the ability of the medication to pass into the bloodstream.With Editas Medicine stock trading at $6.26 per share, the total value of Editas Medicine stock (market capitalization) is $511.02M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an ...Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Shares of Editas Medicine (EDIT 3.66%) ... which have yet to be adequately reflected in stock prices. Of course, the flip side is that the merger doesn't make as much sense for Beam Therapeutics. ...Snap's stock is now far below its all-time high of close to $80 in 2021, but patient investors could see shares reach and exceed that price. Prosper Junior Bakiny has no position in any of the ...CAMBRIDGE, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical data from the Phase 1/2 BRILLIANCE trial ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...For Editas Medicine stock forecast for 2031, 12 predictions are offered for each month of 2031 with average Editas Medicine stock forecast of $8.2, a high forecast of $8.21, and a low forecast of $8.19. The average Editas Medicine stock forecast 2031 represents a 4.21% increase from the last price of $7.86999988555908.
Editas Medicine (EDIT) Stock Price Performance. Editas Medicine (EDIT) Stock Key Data. ... Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.The sale of Editas stock could be related to the biotech's upcoming announcement of clinical data. ... Price as of November 29, 2023, 4:00 p.m. ET ... Keith Speights owns shares of Editas Medicine ...Conference Call. The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the third quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas …Instagram:https://instagram. vleo stock price jeff bezosnames for llctio stock newsbloomberg terminal alternative for retail investors Editas Medicine (EDIT 4.03%) ... Could Editas Medicine be a millionaire-maker stock over the next 10 to 20 years? ... Stock Advisor list price is $199 per year. roots reit reviewhit bbw EDIT Editas Medicine Inc. 10.57 -0.15 ( -1.40%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats. medtronic stock forecast Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Our indicative theme on Gene Editing Stocks - which includes names such as CRISPR Therapeutics, Editas Medicine, and others - has returned about 230% over the past 2 years, compared to the broader ...